Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announce that, the Company has received the Acceptance Notice issued by the National Medical Products Administration of the PRC (the "NMPA"). The investigational new drug (the "IND") application for Phase II clinical trial of FZJ-003 capsule namely the oral selective inhibitor for JAK1 (strength: 25mg and 50mg) (the "Drug") on moderate-to-severe atopic dermatitis (the "AD") has been accepted. AD is a chronic inflammatory disease, usually in the form of rash. At least 250 million people worldwide are troubled by AD, and the incidence of AD patients in China is about 10%. At present, 40% of the patients are patients with moderate and severe AD with rash covering most parts of the body, accompanied by severe and continuous pruritus, dry skin, cracking, redness or darkening, crusting or exudation, etc. Itching usually causes sleep disorders, which seriously affects the quality of life. At present, biological agents play a leading role in the treatment of moderate and severe AD, but oral JAK preparations also show amazing effects in clinical research. At the same time, they also have natural advantages of onset time and use mode.